Definium's new psychedelics data, and a reprieve for international scientists

International scientists face increasing uncertainty due to proposed U.S. visa restrictions, specifically a four-year cap on duration of status that threatens the stability of the biomedical research workforce. With international researchers comprising roughly 60% of postdocs in life sciences, these policies risk driving top talent to more welcoming nations like Germany and Canada. Journalist Jonathan Wosen and Dr. Fanta Aw of NAFSA emphasize that the U.S. already possesses robust tracking systems, rendering these new barriers redundant and counterproductive to scientific innovation. Beyond immigration, the biotech sector is seeing significant developments, including the first potential LSD-based therapy for anxiety, the approval of Scholar Rock’s muscle-preserving drug for spinal muscular atrophy, and Novo Nordisk’s strategic shift toward consumer-focused branding. These trends underscore a broader evolution in both the regulatory environment for research and the commercialization strategies of major pharmaceutical companies.